A Phase II Study of the PARP Inhibitor Olaparib (AZD2281) Alone and in Combination With AZD1775, AZD5363, or AZD6738 in Advanced Solid Tumors

Trial Profile

A Phase II Study of the PARP Inhibitor Olaparib (AZD2281) Alone and in Combination With AZD1775, AZD5363, or AZD6738 in Advanced Solid Tumors

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Apr 2018

At a glance

  • Drugs Olaparib (Primary) ; AZD 5363; AZD 6738; AZD-1775
  • Indications Solid tumours
  • Focus Therapeutic Use
  • Acronyms OLAPCO
  • Most Recent Events

    • 10 Apr 2018 AZD-2014 removed from the study, and drug AZD6738 has been added.
    • 24 Nov 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
    • 17 Nov 2015 Planned initiation date changed from 1 Oct 2015 to 1 Dec 2015 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top